VRTX Q1 2018 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$125B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$641M-10.3% YoY

Gross Profit

$569M88.8% margin

Operating Income

$129M20.1% margin

Net Income

$210M32.8% margin

EPS (Diluted)

$0.81

QoQ Revenue Growth

-1.7%

Cash Flow

Operating Cash Flow

$253M

Free Cash Flow

$223M

Stock-Based Comp.

$78M

Balance Sheet

Total Assets

$4.0B

Total Liabilities

$1.5B

Stockholders' Equity

$2.4B

Cash & Equivalents

$2.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$641M	$715M	-10.3%
Gross Profit	$569M	$668M	-14.8%
Operating Income	$129M	$271M	-52.4%
Net Income	$210M	$248M	-15.1%

Revenue Segments

ORKAMBI

$354M56%

KALYDECO

$250M39%

SYMDEKO/SYMKEVI

$34M5%

Geographic Segments

UNITED STATES

$483M62%

Non-US

$158M20%

Europe

$132M17%